The first report validated the safety and therapeutic efficacy of NOA-16 in the patients newly diagnosed with malignant astrocytoma harboring the IDH1 mutation (NCT02454634) [117]. The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).